Experimental clinical use under psychiatric supervision. A single dose has produced rapid and sustained symptom reductions in cancer-related anxiety/depression (up to 6 months).
A single dose has produced marked and lasting reductions in depression and anxiety in patients with cancer; efficacy in treatment-resistant depression; success rate ≈80% in some trials.
View the study (RCT) →Preliminary efficacy in smoking cessation.
View the study (pilot RCT) →Psilocin extended human cell lifespan by +29% (lung/skin) and increased SIRT1; treated mice showed 80% survival versus 50% in controls.
View the study (preclinical) →*⏱ 2 min read
Psilocybin is a naturally occurring psychedelic compound found in more than 200 species of mushrooms and has a long history of use in indigenous cultures for religious and healing purposes; chemically, psilocybin is rapidly metabolized into psilocin, which acts as a serotonin 2A receptor agonist, producing profound alterations of consciousness; in clinical settings it is administered as a synthesized compound under highly controlled conditions, with extensive participant preparation and professional support.
The most prominent clinical uses of psilocybin include the treatment of anxiety and depression, especially in patients with life-threatening cancer diagnoses, where a single dose has been shown to produce rapid and sustained symptom reductions lasting up to six months; emerging research also suggests efficacy in treatment-resistant depression and smoking cessation, driven by psilocybin's ability to promote neuroplasticity and reorganize psychological perspectives in lasting ways.
A new study suggests it may be time to think of psilocybin as a longevity molecule: in the in vitro component, human lung and skin cells exposed to psilocin extended their lifespan by 29%, slowed the exhaustion of their replicative capacity, and reduced telomere shortening; at a tenfold higher dose, a 57% extension was observed, and psilocin also raised sirtuins such as SIRT1 and reduced markers of DNA damage and oxidative stress in a dose-dependent manner.
In the in vivo component, 19-month-old female mice, equivalent to humans aged about 60-65 years, received a monthly dose of psilocybin for 10 months; 80% of the treated mice survived versus only 50% of the untreated ones, and in addition the mice treated with psilocybin showed improvements in coat quality, hair growth, and less graying, which suggests that the anti-aging effects go beyond survival and directly affect phenotypic markers of aging, independently of its psychedelic properties.
Information, not medical advice. Scientific evidence reflects the quality of the studies.